Response to "Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis"

Future OncologyVol. 19, No. 35 Letter to the EditorResponse to “Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis”Florian Herms & Nicole Basset-SeguinFlorian Herms *Author for correspondence: E-mail Address: florian.herms@aphp.frhttps://orcid.org/0000-0003-3052-6997Hôpital Saint-Louis, Paris, 75010, FranceUniversité Paris Diderot, Paris, 75010, FranceSearch for more papers by this author & Nicole Basset-SeguinHôpital Saint-Louis, Paris, 75010, FranceUniversité Paris Diderot, Paris, 75010, FranceSearch for more papers by this authorPublished Online:15 Nov 2023https://doi.org/10.2217/fon-2022-1290AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View article"Response to “Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis”." Future Oncology, 19(35), pp. 2335–2336References1. Ge W, Chen CI, Wu N et al. Future Oncol. doi: 10.2217/fon-2022-0373 (2022) (Epub ahead of print).Google Scholar2. Gutzmer R, Schulze H-J, Leiter U et al. J. Eur. Acad. Dermatol. Venereol. 35(8), 1678–1685 (2021).Crossref, Medline, CAS, Google Scholar3. Sekulic A, Yoo S, Kudchadkar R et al. PLOS One 17(1), e0262151 (2022).Crossref, Medline, CAS, Google Scholar4. Verkouteren B, Wakkee M, Reyners AKL et al. Br. J. Cancer 124(7), 1199–1206 (2021).Crossref, Medline, CAS, Google Scholar5. Herms F, Lambert J, Grob JJ et al. J. Clin. Oncol. 37(34), 3275–3282 (2019).Crossref, Medline, CAS, Google Scholar6. Bassompierre A, Dalac S, Dreno B et al. ESMO Open 6(6), 100284 (2021).Crossref, Medline, CAS, Google Scholar7. Stratigos A, Sekulic A, Peris K et al. Lancet Oncol. 22(6), 848–857 (2021).Crossref, Medline, CAS, Google Scholar8. Stratigos A et al. Presented at: EADO Congress, Seville (April 21–23, 2022).Google ScholarFiguresReferencesRelatedDetails Vol. 19, No. 35 STAY CONNECTED Metrics Downloaded 2 times History Received 22 December 2022 Accepted 11 October 2023 Published online 15 November 2023 Published in print November 2023 Information© 2023 Future Medicine LtdFinancial disclosureThe authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Competing interests disclosureF Herms: consulting for Sun Pharma and Sanofi; N Basset-Seguin: consulting for Sun Pharma, Sanofi and Galderma. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.Writing disclosureNonfunded writing assistance supplied by Sun Pharma.PDF download